PCV chemotherapy for recurrent glioblastoma multiforme
Abstract
The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status ≥ 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Rajan B, Ross G, Lim CC, et al. Survival of patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Eur J Cancer . 1994; 30A: 1808–1815.
2.
Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol . 1999; 17: 2572–2578.
3.
Gutin PH, Wilson CB, Kumar ARV, et al. Phase II study of procarbazine, CCNU, and vincristine combination chemother- apy in the treatment of malignant brain tumors. Cancer . 1975; 35: 1398–1404.
4.
Levin VA, Edwards MS, Wright DC, et al. Modified procarbazine, CCNU and vincristine (PCV) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep . 1980; 64: 237–241.
5.
Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol . 1994; 12: 2013–2021.
6.
Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol . 1990; 8: 1277–1280.
7.
Yung A, Levin V, Albright R, et al. Randomized trial of temodal versus procarbazine in glioblastoma multiforme at first relapse. J Neurooncol . 1998; 39: 102.Abstract.
8.
Levin VA, Wara WM, Davis RL, et al. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg . 1985; 63: 218–223.
9.
van den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology . 1998; 51: 1140–1145.
10.
Postma TJ, van Groeningen CJ, Witjes RJGM, Weerts JGE, Kralendonk JH, Heimans JJ. Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. J Neurooncol . 1998; 38: 69–75.
Information & Authors
Information
Published In
Copyright
© 2001.
Publication History
Received: April 17, 2000
Accepted: August 24, 2000
Published online: January 9, 2001
Published in issue: January 9, 2001
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Ibrutinib as treatment for Bing–Neel syndrome reclassified as glioblastoma: a case report, Journal of Medical Case Reports, 18, 1, (2024).https://doi.org/10.1186/s13256-024-04757-z
- Epidemiology and outcome of glioblastoma multiforme: A tertiary care experience, Asian Journal of Oncology, 9, (3), (2023).https://doi.org/10.25259/ASJO-2022-65-(429)
- Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival, Neuro-Oncology, 25, 6, (1017-1028), (2023).https://doi.org/10.1093/neuonc/noad002
- Updates in the Management of Recurrent Glioblastoma Multiforme, Journal of Neurological Surgery Part A: Central European Neurosurgery, 84, 02, (174-187), (2022).https://doi.org/10.1055/s-0042-1749351
- Metachronous Osseous Metastases From Gliobliostoma Mutiforme: An Unusual Presentation, Cureus, (2022).https://doi.org/10.7759/cureus.22587
- 1 Natural History and Management Options of Recurrent Glioblastoma glioblastoma (GBM) recurrence of management options of glioblastoma (GBM) recurrence of history of, Neurosurgical Diseases, (2022).https://doi.org/10.1055/b-0041-184132
- Role of Polymeric Local Drug Delivery in Multimodal Treatment of Malignant Glioma: A Review, International Journal of Nanomedicine, Volume 16, (4597-4614), (2021).https://doi.org/10.2147/IJN.S309937
- Current FDA-Approved Therapies for High-Grade Malignant Gliomas, Biomedicines, 9, 3, (324), (2021).https://doi.org/10.3390/biomedicines9030324
- Current status of recurrent glioblastoma therapies, New Targeting in the Reversal of Resistant Glioblastomas, (1-7), (2021).https://doi.org/10.1016/B978-0-12-822527-1.00015-0
- Dissecting and rebuilding the glioblastoma microenvironment with engineered materials, Nature Reviews Materials, 4, 10, (651-668), (2019).https://doi.org/10.1038/s41578-019-0135-y
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.